IL1B and Alzheimer disease: Neuroinflammation is an important AD pathoetiologic hallmark [38], and β-amyloid deposit-associated microgliosis and astrocytosis were reduced in FA-treated PSAPP mice, along with decreased expression of proinflammatory cytokines (TNF-α and IL-1β).